摘要
虹膜新生血管是眼内新生血管的一种表现,血管内皮生长因子(vascular endothelial growth factor,VEGF)是迄今为止鉴定出来最重要的血管生成因子,与新生血管形成和通透性紧密相关。贝伐单抗是人源化的抗VEGF重组鼠单克隆抗体,可与所有已知VEGF异构体结合,通过抑制其生物学活性来抑制新生血管的生成。临床研究此药治疗虹膜新生血管在短期内取得了良好的疗效、且安全可靠。本文就最近几年国内外有关治疗虹膜新生血管疾病的研究进行综述,评估其在虹膜新生血管治疗方面的应用前景。
Iris neovascularisation is a manifestation of intraocular neovascularization.Vascular endothelial growth factor（VEGF）has been identified as the most important angiogenesis factor,which is closely related to formation and permeability of neovascularization.Bevacizumab is a humanized recombinant anti-VEGF mouse monoclonal antibody,which can bind to all isomerides of VEGF and inhibit angiogenesis by inhibiting its biological activity.Clinical application of Bevacizumab for the treatment of iris neovascularization has obtained a good and safe efficacy in a short term.This paper reviews research findings in the treatment of iris neovascularization at home and abroad in recent years,and also evaluates prospects in the treatment of iris neovascularization.
出处
《眼科新进展》
CAS
北大核心
2010年第5期493-496,共4页
Recent Advances in Ophthalmology
关键词
血管内皮生长因子
贝伐单抗
虹膜新生血管
vascular endothelial growth factor
Bevacizumab
iris neovascularization
